Evidence map›Paper›PMID 30779811›Full record

ArticlePLoS pathogens2019

Identification of HIV gp41-specific antibodies that mediate killing of infected cells.

Katherine L Williams, Megan Stumpf, Nicole Elise Naiman, Shilei Ding, Meghan Garrett, Theodore Gobillot, Dani Vézina, Katharine Dusenbury, Nitya S Ramadoss, Ryan Basom and 3 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 41 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Katherine L WilliamsDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle WA, United States of America.
Megan StumpfDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle WA, United States of America.ORCID 0000-0001-8085-3094
Nicole Elise NaimanDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle WA, United States of America.
Shilei DingDepartment of Microbiology, Infectious Diseases and Immunology, Université de Montréal, Montreal, QC, Canada.
Meghan GarrettDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle WA, United States of America.ORCID 0000-0002-3284-3307
Theodore GobillotDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle WA, United States of America.ORCID 0000-0002-4313-3204
Dani VézinaDepartment of Microbiology, Infectious Diseases and Immunology, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0002-0780-8593
Katharine DusenburyMedical Scientist Training Program, University of Washington, Seattle WA, United States of America.ORCID 0000-0002-6223-4019
Nitya S RamadossStanford ChEM-H and Department of Biochemistry, Stanford University, Stanford, CA, United States of America.ORCID 0000-0001-8407-8822
Ryan BasomGenomics and Bioinformatics Shared Resource, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.ORCID 0000-0001-6137-1807
Peter S KimStanford ChEM-H and Department of Biochemistry, Stanford University, Stanford, CA, United States of America.
Andrés FinziDepartment of Microbiology, Infectious Diseases and Immunology, Université de Montréal, Montreal, QC, Canada.
Julie OverbaughDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle WA, United States of America.ORCID 0000-0002-0239-9444
Fred Hutch Cancer Center · USUniversity of Washington · USUniversité de Montréal · CAChan Zuckerberg Initiative (United States) · USStanford University · US

Funding

University of Washington Medical Scientist Training Program: MD/PhDT32GM007266 · NIGMS · UNIVERSITY OF WASHINGTON · PI HORWITZ, MARSHALL S. · 1985 to 2023
$30.4M
INTERDISCIPLINARY TRAINING IN GENOMIC SCIENCEST32HG000035 · NHGRI · UNIVERSITY OF WASHINGTON · PI Bruce Colston Trapnell · 1995 to 2026
$24.2M
VENEREAL DISEASET32AI007140 · NIAID · UNIVERSITY OF WASHINGTON · PI Julia Cook Dombrowski · 1985 to 2026
$19.4M
EARLY INFECTION IN WOMEN EXPOSED MUCOSALLY TO HIV-1R37AI038518 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI OVERBAUGH, JULIE M. · 1999 to 2019
$12.9M
Viral Pathogenesis Training ProgramT32AI083203 · NIAID · UNIVERSITY OF WASHINGTON · PI BLOOM, JESSE D, LAGUNOFF, MICHAEL · 2009 to 2023
$2.7M
Defining the Prevalence and Viral Genetics of Zika Virus in KenyaF30AI142870 · NIAID · UNIVERSITY OF WASHINGTON · PI GOBILLOT, THEODORE AUGUST · 2019 to 2021
$131k
NIAID NIH HHS F30 AI142870NIAID NIH HHS R37 AI038518NIAID NIH HHS T32 AI007140NIAID NIH HHS T32 AI083203NIGMS NIH HHS T32 GM007266
6 · The paper itself

Abstract

Antibodies that mediate killing of HIV-infected cells through antibody-dependent cellular cytotoxicity (ADCC) have been implicated in protection from HIV infection and disease progression. Despite these observations, these types of HIV antibodies are understudied compared to neutralizing antibodies. Here we describe four monoclonal antibodies (mAbs) obtained from one individual that target the HIV transmembrane protein, gp41, and mediate ADCC activity. These four mAbs arose from independent B cell lineages suggesting that in this individual, multiple B cell responses were induced by the gp41 antigen. Competition and phage peptide display mapping experiments suggested that two of the mAbs target epitopes in the cysteine loop that are highly conserved and a common target of HIV gp41-specific antibodies. The amino acid sequences that bind these mAbs are overlapping but distinct. The two other mAbs were competed by mAbs that target the C-terminal heptad repeat (CHR) and the fusion peptide proximal region (FPPR) and appear to both target a similar unique conformational epitope. These gp41-specific mAbs mediated killing of infected cells that express high levels of Env due to either pre-treatment with interferon or deletion of vpu to increase levels of BST-2/Tetherin. They also mediate killing of target cells coated with various forms of the gp41 protein, including full-length gp41, gp41 ectodomain or a mimetic of the gp41 stump. Unlike many ADCC mAbs that target HIV gp120, these gp41-mAbs are not dependent on Env structural changes associated with membrane-bound CD4 interaction. Overall, the characterization of these four new mAbs that target gp41 and mediate ADCC provides evidence for diverse gp41 B cell lineages with overlapping but distinct epitopes within an individual. Such antibodies that can target various forms of envelope protein could represent a common response to a relatively conserved HIV epitope for a vaccine.

Indexed as

Amino Acid SequenceAntibodies, MonoclonalAntibodies, NeutralizingAntibody-Dependent Cell CytotoxicityEnzyme-Linked Immunosorbent AssayEpitopesHIV-1HIV AntibodiesHIV Envelope Protein gp41HIV InfectionsHumansNeutralization TestsAntibodies, MonoclonalAntibodies, NeutralizingEpitopesHIV AntibodiesHIV Envelope Protein gp41

Identifiers

PMID30779811
PMCPMC6396944
OpenAlexW2915804137

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.